Reviewing Addex Therapeutics (OTCMKTS:ADDXF) & Rallybio (NASDAQ:RLYB)

Rallybio (NASDAQ:RLYB) and Addex Therapeutics (OTCMKTS:ADDXF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, risk, valuation, institutional ownership, earnings, analyst recommendations and profitability.

Profitability

This table compares Rallybio and Addex Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rallybio	N/A	-77.39%	-69.33%
Addex Therapeutics	N/A	N/A	N/A

Institutional and Insider Ownership

90.3% of Rallybio shares are owned by institutional investors. 7.4% of Rallybio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Rallybio and Addex Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rallybio	$636,000.00	16.38	-$74.56 million	($1.35)	-0.19
Addex Therapeutics	N/A	N/A	N/A	N/A	N/A

Addex Therapeutics has lower revenue, but higher earnings than Rallybio.

Risk & Volatility

Rallybio has a beta of -1.35, meaning that its share price is 235% less volatile than the S&P 500. Comparatively, Addex Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Rallybio and Addex Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rallybio	0	3	2	0	2.40
Addex Therapeutics	0	0	0	0	0.00

Rallybio presently has a consensus target price of $9.33, indicating a potential upside of 3,628.86%. Given Rallybio’s stronger consensus rating and higher probable upside, equities analysts clearly believe Rallybio is more favorable than Addex Therapeutics.

Summary

Rallybio beats Addex Therapeutics on 6 of the 9 factors compared between the two stocks.

About Rallybio

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

About Addex Therapeutics

Addex Therapeutics Ltd, a development-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of oral small molecule allosteric modulators of G-protein coupled receptors. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia, and dystonia; ADX71149 for epilepsy and undisclosed CNS disorders; and GABAB PAM for addiction. It has license and collaboration agreement with Janssen Pharmaceuticals Inc.; Indivior PLC; and The Charcot-Marie-Tooth Association. The company was formerly known as Addex Pharmaceuticals Ltd and changed its name to Addex Therapeutics Ltd in March 2012. Addex Therapeutics Ltd was founded in 2002 and is headquartered in Geneva, Switzerland.